Daphnetin plus chemo for advanced ovarian cancer maintenance
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial is testing a combination of two drugs—daphnetin capsules and a standard chemotherapy (TC regimen)—as a targeted maintenance therapy after initial surgery for advanced ovarian cancer. The goal is to see if this treatment can help keep the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have stage 3 or 4 ovarian cancer and have not had any chemotherapy or other treatment yet.
- You had surgery that removed all or almost all of the visible tumor (R0 or R1).
- You are generally healthy enough to be up and active (ECOG score 0 or 1).
- Your organs and bone marrow are working well enough.
- You are willing to provide a tumor sample from a past biopsy or surgery (or have a new one taken).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called BL-B01D1 against standard chemotherapy for people with ovarian cancer that no longer responds to platinum-based treatments. The goal is to see which option works better.
This trial tests whether taking fluzoparib (a PARP inhibitor) plus apatinib (a targeted therapy) after initial chemotherapy can help keep advanced ovarian, fallopian tube, or primary peritoneal cancer from coming back. It is for people who have finished their first treatment and are in good overall health.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
This Phase 2 trial tests giving chemotherapy before surgery, then continuing two medicines afterward (olaparib and pembrolizumab). It’s designed for people with newly diagnosed Stage III/IV ovarian, fallopian tube, or primary peritoneal cancer who may benefit from tighter control of the disease.
This study tests whether a new targeted drug (distamab vedotin) combined with standard chemo (carboplatin) works better than chemo alone for women with advanced ovarian cancer that has high levels of HER2. It is for women who have not had chemotherapy yet and have already had surgery to remove the tumor.
This Phase 2 trial compares two different treatment strategies as the first chemotherapy after surgery for advanced epithelial ovarian, peritoneal, or fallopian-tube cancer. It may help doctors find a more effective or better-tolerated approach for people in your situation.
Hear when a new Epithelial Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.